Literature DB >> 31145896

CXC chemokine ligand 12 (CXCL12) in atherosclerosis: An underlying therapeutic target.

Jia-Hui Gao1, Xiao-Hua Yu1, Chao-Ke Tang2.   

Abstract

CXC chemokine ligand 12 (CXCL12) is a specific chemokine ligand and plays a significant role in cell chemotaxis. Upon binding to CXC chemokine receptor 4 (CXCR4) or CXCR7, CXCL12 can activate different signaling cascades to regulate cell proliferation, migration, and metabolism. CXCL12 exerts a pro-atherogenic action by aggravating multiple pathogenesis of atherogenesis, including dyslipidemia, inflammation, neointima hyperplasia, angiogenesis, and insulin resistance. Serum CXCL12 levels are also markedly increased in patients with atherosclerosis-associated disease. The present review focuses on recent advances in CXCL12 research in the pathogenesis of atherosclerosis together with its clinical values. This may provide insight into potential novel therapies for atherosclerosis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; CXCL12; CXCR4; CXCR7

Mesh:

Substances:

Year:  2019        PMID: 31145896     DOI: 10.1016/j.cca.2019.05.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  10 in total

1.  Macrophage-Specific IGF-1 Overexpression Reduces CXCL12 Chemokine Levels and Suppresses Atherosclerotic Burden in Apoe-Deficient Mice.

Authors:  Patricia Snarski; Sergiy Sukhanov; Tadashi Yoshida; Yusuke Higashi; Svitlana Danchuk; Bysani Chandrasekar; Di Tian; Vikara Rivera-Lopez; Patrick Delafontaine
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-12-02       Impact factor: 8.311

2.  Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: is there an association?

Authors:  Manol Jovani; Elizabeth E Liu; Samantha M Paniagua; Emily S Lau; Shawn X Li; Katherine S Takvorian; Bernard E Kreger; Greta Lee Splansky; Rudolf A de Boer; Amit D Joshi; Shih Jen Hwang; Chen Yao; Tianxiao Huan; Paul Courchesne; Martin G Larson; Daniel Levy; Andrew T Chan; Jennifer E Ho
Journal:  Cardiovasc Res       Date:  2022-07-27       Impact factor: 13.081

3.  CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway.

Authors:  Jia-Hui Gao; Lin-Hao He; Xiao-Hua Yu; Zhen-Wang Zhao; Gang Wang; Jin Zou; Feng-Jiao Wen; Li Zhou; Xiang-Jun Wan; Da-Wei Zhang; Chao-Ke Tang
Journal:  J Lipid Res       Date:  2019-10-29       Impact factor: 5.922

Review 4.  Role and implications of the CXCL12/CXCR4/CXCR7 axis in atherosclerosis: still a debate.

Authors:  Hussam A S Murad; Misbahuddin M Rafeeq; Thamer M A Alqurashi
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

5.  The role of blood CXCL12 level in prognosis of coronary artery disease: A meta-analysis.

Authors:  Shunrong Zhang; Yu Ding; Fei Feng; Yue Gao
Journal:  Front Cardiovasc Med       Date:  2022-07-27

6.  Circulating Ageing Neutrophils as a Marker of Asymptomatic Polyvascular Atherosclerosis in Statin-Naïve Patients without Established Cardiovascular Disease.

Authors:  Vadim Genkel; Ilya Dolgushin; Irina Baturina; Albina Savochkina; Karina Nikushkina; Anna Minasova; Lubov Pykhova; Veronika Sumerkina; Alla Kuznetsova; Igor Shaposhnik
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208

7.  Association of SDF1 and MMP12 with Atherosclerosis and Inflammation: Clinical and Experimental Study.

Authors:  María Marcos-Jubilar; Josune Orbe; Carmen Roncal; Florencio J D Machado; José Antonio Rodriguez; Alejandro Fernández-Montero; Inmaculada Colina; Raquel Rodil; Juan C Pastrana; José A Páramo
Journal:  Life (Basel)       Date:  2021-05-01

8.  Foam cells promote atherosclerosis progression by releasing CXCL12.

Authors:  Lingxing Li; Zhenlan Du; Bing Rong; Dapeng Zhao; Aiping Wang; Yuzhen Xu; Huanyi Zhang; Xue Bai; Jingquan Zhong
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

9.  Synergistic effect of collagen and CXCL12 in the low doses on human platelet activation.

Authors:  Daiki Nakashima; Takashi Onuma; Kumiko Tanabe; Yuko Kito; Kodai Uematsu; Daisuke Mizutani; Yukiko Enomoto; Masanori Tsujimoto; Tomoaki Doi; Rie Matsushima-Nishiwaki; Haruhiko Tokuda; Shinji Ogura; Toru Iwama; Osamu Kozawa; Hiroki Iida
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

10.  lncRNA MEG3 aggravated neuropathic pain and astrocyte overaction through mediating miR-130a-5p/CXCL12/CXCR4 axis.

Authors:  Jiacai Dong; Rui Xia; Zhonggui Zhang; Cheng Xu
Journal:  Aging (Albany NY)       Date:  2021-10-05       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.